At Inbeeo, Market Access truly is our passion and we love to share our thoughts on the latest developments in the field through our blog and also in publications. Should you have a topic that you would value our thoughts on then please do get in touch – we would love to hear from you.

The Inbeeo Market Access Consulting Team

A tailored approach to estimate the outlook of the gene therapy market 

Using epidemiological data, a patient-based forecasting model projected the gene therapy market outlook until 2036, evaluating global developments and their impact. Despite uncertainties, it emphasized the importance of preparedness and sustainability for public health resource stakeholders.

Advanced Access for Advanced Therapies

Out with the old, in with the new. What worked for small molecules and MAbs is irrelevant. We co-hosted this webinar with Impatient to help the audience uncover strategic frameworks, tailored for ATMP access challenges.

Will Europe Miss The Boat On ATMPs?

Europe is lagging behind in the adoption of ATMPs, as seen in its low profitability and R&D spending compared to other regions. This is largely due to the challenges faced in clinical assessments of ATMPs and the need for innovative pricing and reimbursement pathways to ensure early patient access.

Four Market Access Measures Triggered By COVID-19 That Are Here To Stay

Four Market Access Measures Triggered by COVID-19 That Are Here To Stay

Many market access decisions were intended to provide rapid one-off answers to one of the most extraordinary situations healthcare systems have ever had to face, but some of them are telling us something about the more profound changes that are likely to affect pharmaceutical market access in the longer run.